Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
PHASE2Active, not recruitingINTERVENTIONAL
Enrollment
48
Participants
Timeline
Start Date
February 1, 2021
Primary Completion Date
November 30, 2025
Study Completion Date
November 30, 2025
Conditions
Lung Small Cell CarcinomaNeuroendocrine CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8